210 related articles for article (PubMed ID: 15969931)
1. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs.
Sakaeda T; Iwaki K; Kakumoto M; Nishikawa M; Niwa T; Jin JS; Nakamura T; Nishiguchi K; Okamura N; Okumura K
J Pharm Pharmacol; 2005 Jun; 57(6):759-64. PubMed ID: 15969931
[TBL] [Abstract][Full Text] [Related]
2. [Drug-drug interaction of antifungal drugs].
Niwa T; Shiraga T; Takagi A
Yakugaku Zasshi; 2005 Oct; 125(10):795-805. PubMed ID: 16205037
[TBL] [Abstract][Full Text] [Related]
3. [Drug interactions in critically-ill patients. An important factor in the use of micafungin?].
Garnacho-Montero J; Jiménez Parrilla F
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():33-7. PubMed ID: 21420575
[TBL] [Abstract][Full Text] [Related]
4. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450.
Niwa T; Imagawa Y; Yamazaki H
Curr Drug Metab; 2014; 15(7):651-79. PubMed ID: 25429674
[TBL] [Abstract][Full Text] [Related]
5. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K
Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility.
Niimi K; Maki K; Ikeda F; Holmes AR; Lamping E; Niimi M; Monk BC; Cannon RD
Antimicrob Agents Chemother; 2006 Apr; 50(4):1148-55. PubMed ID: 16569823
[TBL] [Abstract][Full Text] [Related]
8. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes.
Niwa T; Shiraga T; Takagi A
Biol Pharm Bull; 2005 Sep; 28(9):1805-8. PubMed ID: 16141567
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP.
Lempers VJ; van den Heuvel JJ; Russel FG; Aarnoutse RE; Burger DM; Brüggemann RJ; Koenderink JB
Antimicrob Agents Chemother; 2016 Jun; 60(6):3372-9. PubMed ID: 27001813
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.
Katoh M; Nakajima M; Yamazaki H; Yokoi T
Pharm Res; 2000 Oct; 17(10):1189-97. PubMed ID: 11145223
[TBL] [Abstract][Full Text] [Related]
11. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
12. Drug-drug interactions of antifungal agents and implications for patient care.
Gubbins PO; Amsden JR
Expert Opin Pharmacother; 2005 Oct; 6(13):2231-43. PubMed ID: 16218884
[TBL] [Abstract][Full Text] [Related]
13. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
Clin Pharmacokinet; 2000 Feb; 38(2):111-80. PubMed ID: 10709776
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants.
Yamaguchi Y; Akiyoshi T; Kawamura G; Imaoka A; Miyazaki M; Guengerich FP; Nakamura K; Yamamoto K; Ohtani H
Drug Metab Pharmacokinet; 2021 Jun; 38():100384. PubMed ID: 33826998
[TBL] [Abstract][Full Text] [Related]
15. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2015 Jun; 39(5):374-86. PubMed ID: 25868557
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
Katoh M; Nakajima M; Yamazaki H; Yokoi T
Eur J Pharm Sci; 2001 Feb; 12(4):505-13. PubMed ID: 11231118
[TBL] [Abstract][Full Text] [Related]
17. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein.
Evans DC; O'Connor D; Lake BG; Evers R; Allen C; Hargreaves R
Drug Metab Dispos; 2003 Jul; 31(7):861-9. PubMed ID: 12814962
[TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein.
Egashira K; Ohtani H; Itoh S; Koyabu N; Tsujimoto M; Murakami H; Sawada Y
Drug Metab Dispos; 2004 Aug; 32(8):828-33. PubMed ID: 15258108
[TBL] [Abstract][Full Text] [Related]
20. Substrate Specificity of Human Cytochrome P450 (CYP) 2C Subfamily and Effect of Azole Antifungal Agents on CYP2C8.
Niwa T; Imagawa Y
J Pharm Pharm Sci; 2016; 19(4):423-429. PubMed ID: 28057172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
